R-Zero, a San Francisco, CA-based biosafety company dedicated to developing hospital-grade technologies to reduce the spread of infectious disease, raised $15M in Series A funding.
The round was led by DBL Partners, with participation from Bedrock Capital and HAX / SOSV. As part of the round, Ira Ehrenpreis, Managing Partner at DBL Partners, has joined R-Zero’s Board of Directors.
This new capital will allow the company to further accelerate production and deployment of its flagship IoT UV-C system while continuing development of new product innovations.
Founded in the early stages of the pandemic by co-founders Ben Boyer, Grant Morgan and Eli Harris, R-Zero is a biosafety company dedicated to making living and working spaces safer and clinically clean. Its suite of hospital-grade technologies and science-backed protocols reduces the transmission of pathogens and the diseases they cause – from the coronavirus to the common cold. R-Zero’s flagship product, Arc, is a touchless, hospital-grade UV-C disinfection device, designed to be operationally accessible to organizations of all shapes and sizes. BLE, LTE-M and GPS connectivity shares usage data in real-time, providing organizations with an auditable trail of all disinfection activities.